المؤلفون: Bergeron, Anne, Mikulska, Małgorzata, de Greef, Julien, Bondeelle, Louise, Franquet, Tomás C., Herrmann, Jean Louis, Lange, Christoph G., Spriet, Isabel, Akova, Murat, Donnelly, J. Peter, Maertens, Johan A., Maschmeyer, Georg, Rovira, Montserrat, Goletti, Delia, de la Camara, R., Greinix, Hildegard Theresia, Slavin, Monica A., Hubacek, Petr, Cordonnier, Catherine, Kanerva, Jukka, Herbrecht, Raoul, Lanternier, Fanny L., Robin, Christine, Einsele, Hermann, Lehrnbecher, Thomas M., Groll, Andreas H., von Lilienfeld-Toal, Marie, Pana, Dorothea, Roilides, Emmanuel J., Kassa, Csaba, Averbuch, Diana, Engelhard, Dan, Cesaro, Simone, Pagano, Livio, Castagnola, Elio, Compagno, Francesca, Mesini, Alessio, Donnelly, Peter J., Styczynski, Jan, Botelho de Sousa, Aida, Aljurf, Mahmoud Deeb, Navarro, David Vicente, Garcia-Vidal, Carol, Ljungman, Per T., Paukssen, Karlis, Ammann, Roland A., Lamoth, Frédéric, Hirsch, Hans H., Ritz, Nicole, Ceesay, Muhammed Mansour, Warris, Adilia, Chemaly, Roy F.

المساهمون: Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Raymond Poincaré (Garches) GHU AP-HP Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)

المصدر: ISSN: 1473-3099.

مصطلحات موضوعية: [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases

الوصف: International audience ; Mycobacterial infections, both tuberculosis and nontuberculous, are more common in patients with haematological malignancies and haematopoietic stem cell transplant recipients than in the general population—although these infections remain rare. Mycobacterial infections pose both diagnostic and therapeutic challenges. The management of mycobacterial infections is particularly complicated for patients in haematology because of the many drug–drug interactions between antimycobacterial drugs and haematological and immunosuppressive treatments. The management of mycobacterial infections must also consider the effect of delaying haematological management. We surveyed the management practices for latent tuberculosis infection (LTBI) in haematology centres in Europe. We then conducted a meticulous review of the literature on the epidemiology, diagnosis, and management of LTBI, tuberculosis, and nontuberculous mycobacterial infections among patients in haematology, and we formulated clinical guidelines according to standardised European Conference on Infections in Leukaemia (ECIL) methods. In this Review, we summarise the available literature and the recommendations of ECIL 8 for managing mycobacterial infections in patients with haematological malignancies.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35636446; hal-03888895; https://hal.science/hal-03888895Test; PUBMED: 35636446

الإتاحة: https://doi.org/10.1016/S1473-3099Test(22)00227-4
https://hal.science/hal-03888895Test

المؤلفون: Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E Gray, John Powderly, Christos Chouaid, Paolo Bidoli, Paul Wheatley-Price, Keunchil Park, Ross A Soo, Yifan Huang, Catherine Wadsworth, Phillip A Dennis, Naiyer A Rizvi, Luis Paz-Ares Rodriguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang-We Kim, Jamie Chaft, David Vicente Baz, Thierry Berghmans, Dong-Wan Kim, Veerle Surmont, Martin Reck, Ji-Youn Han, Esther Holgado Martin, Cristobal Belda Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, Gilles Robinet, Hector Soto Parra, Michael Thomas, Parneet Cheema, Nobuyuki Katakami, Wu-Chou Su, Young-Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Milella, Inmaculada Ramos Garcia, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, Ernst Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Remi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoine Italiano, Dariusz Kowalski, Fabrice Barlesi, Yuh-Min Chen, David Spigel, Busyamas Chewaskulyong, Ramon Garcia Gomez, Rosa Alvarez Alvarez, Chih-Hsin Yang, Te-Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Koichi Goto, Joaquim Bosch-Barrera, Glen Weiss, Jean-Luc Canon, Christian Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius Waller, David Waterhouse, Bruno Coudert, Zsuzsanna Mark, Miyako Satouchi, Gee-Chen Chang, Christian Herzmann, Arvind Chaudhry, Selvaraj Giridharan, Paul Hesketh, Norihiko Ikeda, Ralph Boccia, Nichola Iannotti, Missak Haigentz, John Reynolds, John Querol, Kazuhiko Nakagawa, Shunichi Sugawara, Eng Huat Tan, Tomonori Hirashima, Scott Gettinger, Terufumi Kato, Koji Takeda, Oscar Juan Vidal, Andrea Mohn-Staudner, Amit Panwalkar, Davey Daniel, Kunihiko Kobayashi, Guia Elena Imelda Ladrera, Clemens Schulte, Martin Sebastian, Marketa Cernovska, Helena Coupkova, Libor Havel, Norbert Pauk, Joginder Singh, Shuji Murakami, Tibor Csoszi, Gyorgy Losonczy, Allan Price, Ian Anderson, Mussawar Iqbal, Vamsee Torri, Erzsebet Juhasz, Saleem Khanani, Leona Koubkova, Benjamin Levy, Ray Page, Csaba Bocskei, Lucio Crinò, David Einspahr, Christopher Hagenstad, Necy Juat, Lindsay Overton, Mitchell Garrison, Zsuzsanna Szalai

المساهمون: IRCCS Istituto Nazionale dei Tumori [Milano], Yonsei University College of Medicine, CHA Bundang Medical Center, Service Pneumologie-Allergologie [CHU Toulouse], Pôle Clinique des Voies respiratoires [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), University Hospitals KU Leuven, Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Universitario Virgen del Rocío [Sevilla], H. Lee Moffitt Cancer Center and Research Institute, Carolina BioOncology Institute, Service de Pneumologie [CHI Créteil], CHI Créteil, IMRB - CEPIA/'Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Azienda Ospedaliera San Gerardo, The Ottawa Hospital Research Institute, Centre for Rehabilitation Research and Development, 505 Smyth Road, Ottawa, ON, Canada, K1H 8M2., Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, National University Hospital and National University Cancer Institute, AstraZeneca, Gaithersburg, MD, USA, AstraZeneca [Cambridge, UK], Columbia University [New York], Università degli studi di Torino = University of Turin (UNITO), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Department of Mathematics [Imperial College London], Imperial College London, Université libre de Bruxelles (ULB), Department of Microbiology, Chang Won National University, German Center for Lung Research, Università degli studi di Palermo - University of Palermo, Garassino, M, Cho, B, Kim, J, Mazieres, J, Vansteenkiste, J, Lena, H, Jaime, J, Gray, J, Powderly, J, Chouaid, C, Bidoli, P, Wheatley-Price, P, Park, K, Soo, R, Huang, Y, Wadsworth, C, Dennis, P, Rizvi, N

المصدر: Lancet Oncology
Lancet Oncology, 2020, 19 (4), pp.521-536. ⟨10.1016/s1470-2045(18)30144-x⟩
Lancet Oncol

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Durvalumab, Lung Neoplasms, Phases of clinical research, B7-H1 Antigen, 0302 clinical medicine, Antineoplastic Agents, Immunological, 4-Butyrolactone, Carcinoma, Non-Small-Cell Lung, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Fatigue, Antibodies, Monoclonal, phase 2 study, gamma-Glutamyltransferase, Middle Aged, Progression-Free Survival, ErbB Receptors, ATLANTIS, Response Evaluation Criteria in Solid Tumors, Oncology, Durvalumab, non-small-cell lung cancer , ATLANTIS, phase 2 study, 030220 oncology & carcinogenesis, Cohort, Female, Immunotherapy, Diarrhea, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Article, 03 medical and health sciences, Internal medicine, medicine, Humans, Progression-free survival, Aspartate Aminotransferases, Lung cancer, Aged, Performance status, business.industry, Pneumonia, medicine.disease, Injection Site Reaction, 030104 developmental biology, non-small-cell lung cancer, Mutation, business

الوصف: Background: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR−/ALK−), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1. Methods: ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centres in Asia, Europe, and North America. Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key exclusion criteria included mixed small-cell lung cancer and NSCLC histology; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent. Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression. Patients in cohorts 2 and 3 had EGFR−/ALK− NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumour cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumour cells with PD-L1 expression. Patients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tumour cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1. Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available. The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, number NCT02087423. Findings: Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3. Among patients with at least 25% of tumour cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7–21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8–23·5) of 146 patients in cohort 2. In cohort 3, 21 (30·9%, 20·2–43·3) of 68 patients achieved an objective response. Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3. The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00025c91c5f85bf7d8b98d17aae85fd1Test
https://hal.u-pec.fr/hal-04145965/documentTest

المؤلفون: David Vicente

المساهمون: Karl-Franzens-Universität Graz, The author is with the Institute of Mathematics and Scientific Computing, University of Graz, Austria. The Institute of Mathematics and Scientific Computing is a member of NAWI Graz (www.nawigraz.at) and BioTechMed Graz (www.biotechmed.at). This work was supported in part by the Austrian Science Fund (FWF) under grant SFB F32 (SFB 'Mathematical Optimization and Applications in Biomedical Sciences').

المصدر: Journal of Mathematical Analysis and Applications
Journal of Mathematical Analysis and Applications, Elsevier, 2017, 447, pp.181-205. ⟨10.1016/j.jmaa.2016.10.008⟩

مصطلحات موضوعية: Applied Mathematics, 010102 general mathematics, Mathematical analysis, Space (mathematics), 01 natural sciences, Image (mathematics), Term (time), 010101 applied mathematics, Γ-convergence, Bounded function, Metric (mathematics), Segmentation, [MATH.MATH-OC]Mathematics [math]/Optimization and Control [math.OC], 0101 mathematics, Analysis, Energy (signal processing), Mathematics

الوصف: International audience; A variational model is introduced for the segmentation problem of thin structures, like tubes or thin plates, in an image. The energy is based on the Mumford-Shah model with a surfacic term perturbed by a Finsler metric. The formulation in the special space of functions with bounded variations is given and, in order to get an energy more adapted for numerics, a result of Γ-convergence is proved.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::827e51a79c24cb967eb4ba8519b348f1Test
https://hal.archives-ouvertes.fr/hal-01393765Test

المؤلفون: David Vicente, Maïtine Bergounioux

المساهمون: Mathématiques - Analyse, Probabilités, Modélisation - Orléans (MAPMO), Centre National de la Recherche Scientifique (CNRS)-Université d'Orléans (UO)

المصدر: Acta Applicandae Mathematicae
Acta Applicandae Mathematicae, Springer Verlag, 2015, pp xx. ⟨10.1007/s10440-014-0002-1⟩

مصطلحات موضوعية: Partial differential equation, Optimization problem, Selection (relational algebra), Applied Mathematics, 010102 general mathematics, segmentation, ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION, 49J40, 49Q20,94A08, Variational method, 02 engineering and technology, Codimension, Topology, 01 natural sciences, Mumford-Shah, Computer Science::Computer Vision and Pattern Recognition, Prior probability, 0202 electrical engineering, electronic engineering, information engineering, 020201 artificial intelligence & image processing, Segmentation, Uniqueness, [MATH.MATH-OC]Mathematics [math]/Optimization and Control [math.OC], 0101 mathematics, Algorithm, Mathematics

الوصف: International audience; We present a variational model to perform the segmentation of thin structures in MRI images (namely codimension 1 objects). It is based on the classical Mumford-Shah functional and we have added geometrical priors as constraints. We precisely describe the structure model (that we call tubes) and write the problem as a bilevel problem. We focus on the lower level optimization problem and give existence, uniqueness and regularity results for the solution. The keypoint is the fact that 2D/3D problems are equivalent to 1D ones. This gives hints to perform an automatic parameter tuning for numerical purpose.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f14c97fcde743b8e0ff872e2fddc4f2Test
https://hal.archives-ouvertes.fr/hal-00918723Test

المؤلفون: Paviot, Jacques

المساهمون: Centre de recherche en histoire européenne comparée (CRHEC), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), éd. Francisco Contente Domingues, José da Silva Horta, Paulo David Vicente, collab. Augusto Mayer da Silva et Luís Manuel de Araújo, Martemyanova, Ekaterina, éd. Francisco Contente Domingues, José da Silva Horta, Paulo David Vicente, collab. Augusto Mayer da Silva et Luís Manuel de Araújo

المصدر: D’Aquém, d’Além e d’Ultramar. Homenagem a António Dias Farinha
éd. Francisco Contente Domingues, José da Silva Horta, Paulo David Vicente, collab. Augusto Mayer da Silva et Luís Manuel de Araújo. D’Aquém, d’Além e d’Ultramar. Homenagem a António Dias Farinha, II, Centro de História, Faculdade de Letras da Universidade de Lisboa, p. 1217-1224, 2015

مصطلحات موضوعية: [SHS.HIST] Humanities and Social Sciences/History, [SHS.HIST]Humanities and Social Sciences/History, ComputingMilieux_MISCELLANEOUS

الوصف: International audience

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f20e242ef96fbb3946ce7857f02870daTest
https://halshs.archives-ouvertes.fr/halshs-01646441Test

المؤلفون: Paviot, Jacques

المساهمون: Centre de recherche en histoire européenne comparée (CRHEC), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), éd. Francisco Contente Domingues, José da Silva Horta, Paulo David Vicente, collab. Augusto Mayer da Silva et Luís Manuel de Araújo

المصدر: Hyper Article en Ligne - Sciences de l'Homme et de la Société ; D’Aquém, d’Além e d’Ultramar. Homenagem a António Dias Farinha ; éd. Francisco Contente Domingues, José da Silva Horta, Paulo David Vicente, collab. Augusto Mayer da Silva et Luís Manuel de Araújo. D’Aquém, d’Além e d’Ultramar. Homenagem a António Dias Farinha, II, Centro de História, Faculdade de Letras da Universidade de Lisboa, p. 1217-1224, 2015

مصطلحات موضوعية: hist, scipo

الوصف: International audience

العلاقة: halshs-01646441; 10670/1.yna3xt; https://halshs.archives-ouvertes.fr/halshs-01646441Test

الإتاحة: https://halshs.archives-ouvertes.fr/halshs-01646441Test